Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Saskia J.A.M. Santegoets"'
Autor:
Sjoerd H. van der Burg, Lilly-Ann van der Velden, Zlatko Trajanoski, Pornpimol Charoentong, Sylvia I. van Egmond, Frits Koning, Vincent van Unen, Vanessa J. van Ham, Ekaterina S. Jordanova, Ilina Ehsan, Renske Goedemans, Saskia J.A.M. Santegoets, Wenbo Ma, Marij J.P. Welters
Supplementary Methods and Tables Supplementary Table S1. Patient characteristics Supplementary Table S2. Antibodies with isotope tags used in CyTOF analysis Supplementary Table S3. Standard therapy of HPV16+ OPSCC patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ca944607b0609ef33b90bc777a9ac23
https://doi.org/10.1158/1078-0432.22465250.v1
https://doi.org/10.1158/1078-0432.22465250.v1
Autor:
Sjoerd H. van der Burg, Lilly-Ann van der Velden, Zlatko Trajanoski, Pornpimol Charoentong, Sylvia I. van Egmond, Frits Koning, Vincent van Unen, Vanessa J. van Ham, Ekaterina S. Jordanova, Ilina Ehsan, Renske Goedemans, Saskia J.A.M. Santegoets, Wenbo Ma, Marij J.P. Welters
Purpose: Human papillomavirus (HPV)–associated oropharyngeal squamous cell cancer (OPSCC) has a much better prognosis than HPV-negative OPSCC, and this is linked to dense tumor immune infiltration. As the viral antigens may trigger potent immunity,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00144b76efba0b8602121e035acd7d92
https://doi.org/10.1158/1078-0432.c.6525974
https://doi.org/10.1158/1078-0432.c.6525974
Autor:
Sjoerd H. van der Burg, Lilly-Ann van der Velden, Zlatko Trajanoski, Pornpimol Charoentong, Sylvia I. van Egmond, Frits Koning, Vincent van Unen, Vanessa J. van Ham, Ekaterina S. Jordanova, Ilina Ehsan, Renske Goedemans, Saskia J.A.M. Santegoets, Wenbo Ma, Marij J.P. Welters
Supplementary Figure S1. Handling of oropharyngeal squamous cell carcinoma (OPSCC) material. Supplementary Figure S2. HPV16-positive OPSCC harbor T-cells that specifically recognize the HPV16 oncoproteins E6 and E7. Supplementary Figure S3. High expr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88fec36f92e185f6364b8b29a8d42950
https://doi.org/10.1158/1078-0432.22465253.v1
https://doi.org/10.1158/1078-0432.22465253.v1
Autor:
Saskia J.A.M. Santegoets, Alfons J.M. van den Eertwegh, Sinead M. Lougheed, Anita G.M. Stam, Helen Gall, Petra E.T. Scholten, Mary B.E. von Blomberg, Erik Hooijberg, Karin Jooss, Nathalie Sacks, Minh Nguyen, Thomas Harding, Kristen Hege, Israel Lowy, Winald R. Gerritsen, Rik J. Scheper, Tanja D. de Gruijl
Publikováno v:
Cancer Research. 68:2538-2538
The effects of a combination of two allogeneic, GM-CSF-secreting prostate cancer cell lines (GVAX Immunotherapy for Prostate Cancer, Cell Genesys, Inc.) and escalating doses of the anti-CTLA4 antibody ipilimumab (MDX-010, Medarex, Inc.) are currently
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf6c9d145052e67a988d24cb5afeea33
https://doi.org/10.1158/1538-7445.am2008-2538
https://doi.org/10.1158/1538-7445.am2008-2538
